Adlon Therapeutics L.P. to Provide Funding Opportunities for Research to Expand Understanding of ADHD
STAMFORD, Conn.--(BUSINESS WIRE)--May 13, 2019--Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., today announced it will issue a funding opportunity for investigator-initiated research (IIR) studies to contribute to the knowledge and understanding of Attention-Deficit/Hyperactivity Disorder (ADHD). Adlon is dedicated to improving the lives of patients with ADHD, and will provide support for studies that contribute to a better understating of the condition in these individuals. Research proposals for this funding will be accepted starting today and through June 14, 2019.
Clinical research conducted under Adlon’s IIR program will be developed and implemented entirely by researchers in the US, with funding provided by Adlon. The design and the results of these studies will be made public through various channels including scientific publications or public websites.
“Through Adlon’s investigator-initiated research initiative, we are pleased to support researchers who wish to scientifically contribute to the broader better understanding of ADHD,” said Monica Kwarcinski, PharmD, vice president, head of Medical Affairs, Purdue Pharma. “We value the pursuit of scientific excellence, and are looking forward to facilitating new research on ADHD.”
Adlon is currently accepting research proposals as follows:
Current diagnostic standards for ADHD rely heavily on patient self-reporting or observer rating, which can be subjective and leave room for interpretation. 1 Research is needed to explore outcomes associated with the utilization of a clinically relevant and objective measure to assist in the assessment of ADHD. Studies may incorporate single or multiple strategies, and preference will be given to research proposals that include innovative methods to assess ADHD beyond patient self-report or observer rating. Findings from this research may be helpful in potentially improving healthcare providers’ ability to more accurately diagnose or rule out ADHD, therefore ensuring only appropriate patients are diagnosed and receive treatment.
There is a need to advance the understanding of the burden from ADHD in adolescents and adults during the early morning and late afternoon/evening hours, times of day not typically covered by commonly-used pharmacologic ADHD treatments. Proposals are requested to study whether there may be a substantial burden associated with ADHD symptoms outside of the typical daytime hours. Studies may evaluate early morning or late afternoon/evening hours, or both. Preference will be given to research proposals that include evaluation at both times of day and include innovative methods of measuring the burden and impact of ADHD. A better understanding of the impact that ADHD has during these times of day could help healthcare providers and patients optimize treatment strategies.
Interested US-based researchers may submit initial applications, including a letter of intent and study concept, through 5:00 PM ET on June 14, 2019. All applications will be evaluated by Adlon’s IIR Review Committee, and a selected set of applicants will be invited to submit a complete study proposal and corresponding budget for evaluation. Additional details on the application process, including required forms, can be found on the Clinical Research page on Adlon’s website.
About Adlon Therapeutics L.P.
Adlon Therapeutics L.P. is a biopharmaceutical company dedicated to developing and providing treatment options for Attention-Deficit/Hyperactivity Disorder (ADHD) and related disorders. Our initial focus is on adults and adolescents who have been diagnosed with ADHD. Adlon is a subsidiary of Purdue Pharma L.P. For more information, please visit www.adlontherapeutics.com.
1 Emser TS, Johnston BA, Steele DJ, et al. Assessing ADHD symptoms in children and adults: evaluating the role of objective measures. Behav Brain Funct. 2018; 14: 11. Accessed Apr 18, 2019. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960089/pdf/12993_2018_Article_143.pdf.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190513005237/en/
CONTACT: Media Contact
KEYWORD: UNITED STATES NORTH AMERICA CONNECTICUT
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Adlon Therapeutics L.P.
Copyright Business Wire 2019.
PUB: 05/13/2019 09:56 AM/DISC: 05/13/2019 09:56 AM